The Russian Sputnik V vaccine is 91.6% effective at preventing symptomatic Covid-19, according to preliminary results from a phase 3 trial published in The Lancet on Tuesday, placing it in a similar league to the mRNA vaccines developed by Pfizer-BioNtech and Moderna.

The publication is important because scientists have previously expressed concern about Russia’s decision to start wide-scale vaccination with Sputnik V before releasing phase 3 trial data for public scrutiny, and the haste with which more than a dozen other nations have approved the shot...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.